Evidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 72
- Positive
- ConsistencyScore™
- 88
- consistent
Supporting studies: Based on 9 studies
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Once-weekly semaglutide improves glycemic control in Korean adults with T2D
Last updated July 5, 2026
Key finding
HbA1c decreased by 1.6% with semaglutide 0.5 mg.
This study evaluated the efficacy and safety of once-weekly semaglutide in Korean adults with type 2 diabetes, showing significant improvements in HbA1c and body weight.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the efficacy and safety of once-weekly semaglutide in Korean adults with type 2 diabetes, showing significant improvements in HbA1c and body weight.
Clinical relevance
These findings are significant as they suggest that semaglutide can be an effective treatment option for managing type 2 diabetes in Korean adults, potentially leading to better health outcomes. Achieving target HbA1c levels is crucial for reducing the risk of diabetes-related complications, making semaglutide a valuable addition to diabetes management strategies.
Keep in mind
Limited to Korean adults, affecting generalizability. Short duration may not capture long-term effects. Potential bias in self-reported outcomes.
Published in
Journal Reference
Publication details and source links for this paper.
Byung-Wan L, Young MC, Sin GK, et al. Efficacy and Safety of Once-Weekly Semaglutide in Korean Adults with Type 2 Diabetes: A Post Hoc Analysis. Diabetes Therapy. 2024;15(2):547-563. doi:10.1007/s13300-023-01515-0
Main Effects
HbA1c decreased by 1.6% with semaglutide 0.5 mg.
Body weight decreased by 4.8 kg with semaglutide 1.0 mg.
87.5% of participants achieved HbA1c <7.0% with semaglutide 1.0 mg.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Semaglutide, Sitagliptin and Body weight, Composite endpoint achievement, HbA1c.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
- Body weight
- Composite endpoint achievement
- HbA1c
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
4
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
4
Related topics
6
Evidence pairs
614
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
DPP-4 Inhibitors and HbA1c
Related evidence
Evidence relationship
DPP-4 Inhibitors and Body Weight
Save evidence
Evidence relationship
GLP-1 Receptor Agonists and HbA1c
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Composite endpoint achievement
Semaglutide → Composite endpoint achievement
Semaglutide → Composite endpoint achievement
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 86
- Strong
- ImpactScore™
- 91
- Very Positive
- ConsistencyScore™
- 82
- consistent
Supporting studies: Based on 11 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerComposite endpoint achievement
Sitagliptin → Composite endpoint achievement
Sitagliptin → Composite endpoint achievement
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- 80% of participants achieved HbA1c <7.0% with semaglutide 0.5 mg.
- 42.9% achieved weight loss ≥5% with semaglutide 0.5 mg.
- 1.8% HbA1c reduction observed with semaglutide 1.0 mg.
Who this applies to
- Korean adults aged 18-75 with type 2 diabetes.
- Individuals not achieving glycemic control with other treatments.
Keep in Mind
- Results may not apply to non-Korean populations.
- Further studies needed to assess long-term safety.
- Effectiveness may vary based on individual patient characteristics.
Between the Lines
- Limited to Korean adults, affecting generalizability.
- Short duration may not capture long-term effects.
- Potential bias in self-reported outcomes.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 86
- Strong
- ImpactScore™
- 91
- Very Positive
- ConsistencyScore™
- 82
- consistent
Supporting studies: Based on 11 studies
View evidenceMedications
GLP-1 Receptor Agonists → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 72
- Positive
- ConsistencyScore™
- 88
- consistent
Supporting studies: Based on 9 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
11 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
11 studies
outcome_hubMeasures HbA1c as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
9 studies
outcome_hubMeasures Body Weight as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Semaglutide and HbA1c
Intervention: SemaglutideOutcome: HbA1c
11 results
All studies on Semaglutide and Body weight
Intervention: SemaglutideOutcome: Body weight
9 results
All studies on Semaglutide
Intervention: Semaglutide
11 results
All studies measuring HbA1c
Outcome: HbA1c
11 results
All studies measuring Body weight
Outcome: Body weight
9 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does DPP-4 Inhibitors improve HbA1c?
Strong Evidence
DPP-4 Inhibitors appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 79.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 11 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does DPP-4 Inhibitors affect body weight?
Strong Evidence
DPP-4 Inhibitors may improve Body Weight.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 8 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.5 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 30 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists appears to improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 85.5 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 31 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetesHigher semaglutide doses improve glucose control in type 2 diabetesNovel Semaglutide Injection Shows Non-Inferior Glycemic ControlOral semaglutide may improve cardiovascular event prevention in type 2 diabetes.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.